Compositions useful as inhibitors of GSK-3

Details Compositions useful as inhibitors of GSK-3 Compositions useful as inhibitors of GSK-3

2011-01-18

2011-01-18

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S122000, C514S256000, C514S275000, C514S234500, C514S252180

Reexamination Certificate

active

07872129

ABSTRACT:
The present invention provides a compound of formula I:or a pharmaceutically acceptable derivative thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK3 mammalian protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.

REFERENCES:
patent: 3755322 (1973-08-01), Winter et al.
patent: 4540698 (1985-09-01), Ishikawa et al.
patent: 4711951 (1987-12-01), Axen et al.
patent: 5124441 (1992-06-01), Carlsson et al.
patent: 6093716 (2000-07-01), Davis et al.
patent: 6184226 (2001-02-01), Chakravarty et al.
patent: 6277989 (2001-08-01), Chakravarty et al.
patent: 6495582 (2002-12-01), Hale et al.
patent: 6528509 (2003-03-01), Hale et al.
patent: 6558657 (2003-05-01), Mandeville, III et al.
patent: 6562971 (2003-05-01), Frauenkron et al.
patent: 6579983 (2003-06-01), Batchelor et al.
patent: 6589958 (2003-07-01), Frietze
patent: 6610677 (2003-08-01), Davies et al.
patent: 6613776 (2003-09-01), Knegtel et al.
patent: 6638926 (2003-10-01), Davies et al.
patent: 6653300 (2003-11-01), Bebbington et al.
patent: 6653301 (2003-11-01), Bebbington et al.
patent: 6656939 (2003-12-01), Bebbington et al.
patent: 6660731 (2003-12-01), Bebbington et al.
patent: 6664247 (2003-12-01), Bebbington et al.
patent: 6696452 (2004-02-01), Davies et al.
patent: 6727251 (2004-04-01), Bebbington et al.
patent: 6841579 (2005-01-01), Plowman et al.
patent: 6846928 (2005-01-01), Bebbington et al.
patent: 6989385 (2006-01-01), Bebbington et al.
patent: 7008948 (2006-03-01), Bebbington et al.
patent: 7087603 (2006-08-01), Bebbington et al.
patent: 7091343 (2006-08-01), Bebbington et al.
patent: 7098330 (2006-08-01), Bebbington et al.
patent: 7115739 (2006-10-01), Bebbington et al.
patent: 7179826 (2007-02-01), Bebbington et al.
patent: 7491730 (2009-02-01), Forster et al.
patent: 2001/0018436 (2001-08-01), Cushing et al.
patent: 2002/0052386 (2002-05-01), Armistead et al.
patent: 2002/0065270 (2002-05-01), Moriarty et al.
patent: 2003/0004161 (2003-01-01), Bebbington et al.
patent: 2003/0064981 (2003-04-01), Knegtel et al.
patent: 2003/0069239 (2003-04-01), Cai et al.
patent: 2003/0069248 (2003-04-01), Chakravarty et al.
patent: 2003/0078166 (2003-04-01), Davies et al.
patent: 2003/0087922 (2003-05-01), Bethiel et al.
patent: 2003/0092714 (2003-05-01), Cao et al.
patent: 2003/0096813 (2003-05-01), Cao et al.
patent: 2003/0096816 (2003-05-01), Cao et al.
patent: 2003/0144309 (2003-07-01), Choon-Moon
patent: 2003/0171389 (2003-09-01), Bemis et al.
patent: 2003/0187002 (2003-10-01), Mortlock et al.
patent: 2003/0199526 (2003-10-01), Choquette et al.
patent: 2003/0207873 (2003-11-01), Harrington
patent: 2004/0002496 (2004-01-01), Bebbington et al.
patent: 2004/0009996 (2004-01-01), Moon et al.
patent: 2004/0023963 (2004-02-01), Cao et al.
patent: 2004/0029857 (2004-02-01), Hale et al.
patent: 2004/0097531 (2004-05-01), Ledeboer et al.
patent: 2004/0157893 (2004-08-01), Bebbington et al.
patent: 2004/0229875 (2004-11-01), Cao et al.
patent: 2005/0038023 (2005-02-01), Bebbington et al.
patent: 2005/0234059 (2005-10-01), Hale et al.
patent: 2006/0270660 (2006-11-01), Charrier et al.
patent: 0019811 (1980-12-01), None
patent: 136976 (1985-04-01), None
patent: 0302312 (1989-02-01), None
patent: 2052487 (1981-01-01), None
patent: 10-130150 (1998-05-01), None
patent: 06-65237 (2007-10-01), None
patent: 9208715 (1992-05-01), None
patent: 9509851 (1995-04-01), None
patent: 9515758 (1995-06-01), None
patent: 9709325 (1997-03-01), None
patent: 9719065 (1997-05-01), None
patent: 9802434 (1998-01-01), None
patent: 9811095 (1998-03-01), None
patent: 9816502 (1998-04-01), None
patent: 9918781 (1999-04-01), None
patent: 9941253 (1999-08-01), None
patent: 9947154 (1999-09-01), None
patent: 9965897 (1999-12-01), None
patent: 0012497 (2000-03-01), None
patent: 0038675 (2000-07-01), None
patent: 0059509 (2000-10-01), None
patent: 0078757 (2000-12-01), None
patent: 0112621 (2001-02-01), None
patent: 0125220 (2001-04-01), None
patent: 0139777 (2001-06-01), None
patent: 0140215 (2001-06-01), None
patent: 0144242 (2001-06-01), None
patent: 0147879 (2001-07-01), None
patent: 0164655 (2001-09-01), None
patent: 0250066 (2002-06-01), None
patent: 02079197 (2002-10-01), None
patent: 0224667 (2003-03-01), None
patent: 0247690 (2003-06-01), None
patent: 2004000833 (2003-12-01), None
patent: 2004013140 (2004-02-01), None
patent: 9614843 (2008-07-01), None
Doble et al., Journal of Cell Science, 116, 1175-1186, 2003.
Charpiot, B. et al., “Quinazolines: Combined type 3 and 4 phosphodiesterase inhibitors”, Bioorg. Med. Chem. Lett, 8 (20), 2891-2896 (1998).
Shikhaliev, K.S. et al., “Heterocyclization of quinazol-2-ylguanidines. 1. Reaction with amino acids”, Chem. Heterocycl. Compd., 35 (7), 818-820 (1999).
Singh, S.P. et al., “Synthesis & Mass Spectra of Some Substituted 2-(2'-Benzazolylamino)pyrimidines”, Indian J. Chem. Sect. B, 22(1); 37-42 (1983).
Ti, J. et al., “Anticandidal activity of pyrimidine-peptide conjugates”, J. Med. Chem., 23(8), 913-918 (1980).
Kretzschmar, E. et al., “Synthese von 2,6-disubstituierten 4-Hydroxy-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidinen”, Pharmazie, 43(7), 475-476 (1988).
Norman, M.H. et al., “Structure-Activity Relationships of a Series of Pyrrolo[3,2-d]pyrimidine Derivatives and Related Compounds as Neuropeptide Y5 Receptor Antagonists”, J. Med. Chem., 43(22), 4288 -4312 (2000).
Nugent, R.A. et al., “Pyrimidine Thioethers: A Novel Class of HIV-1 Reverse Transcriptase Inhibitors with Activity Against BHAP-Resistant HIV”, J. Med. Chem., 41, 3793-3803 (1998).
Myers, M.R. et al., “The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity”, Bioorg. Med. Chem. Lett., 7, 4, 421-424 (1997).
Agarwal, N. et al., “Suitably functionalised pyrimidines as potential antimycotic agents”, Bioorg. Med. Chem. Lett., 10, 8, 703-706 (2000).
Crespo, M.I. et al., “Design, Synthesis, and Biological Activities of New Thieno[3,2-d]pyrimidines as Selective Type 4 Phosphodiesterase Inhibitors”, J. Med. Chem., 41 (21), 4021-4035 (1998).
Noell, C.W. et al., “Potential Purine Antagonists. XX. The Preparation and Reactions of Some Methylthiopurines”, J. Am. Chem. Soc., 81(22), 5997-6007 (1959).
Lubbers, T. et al., “Design, synthesis, and structure—activity relationship studies of ATP analogues as DNA gyrase inhibitors”, Bioorg. Med. Chem. Lett., 10,8, 821-826 (2000).
D'Atri, G. et al., “Novel pyrimidine and 1,3,5-triazine hypolipemic agents”, J. Med. Chem. 27(12), 1621-1629 (1984).
Venugopalan, B. et al., “Synthesis and antimalarial activity of pyrido[3,2-f)quinozalines and their oxides”, Indian J. Chem. Sect. B, 34, 9, 778-790 (1995).
Curd, F.H.S. et al, “Synthetic antimalarials. Part XVII. Some aminoalkylaminoquinoline derivatives”, J. Chem. Soc., 899-909 (1947).
Haworth, R.D. et al., “Synthetic antimalarials. Part XXVII. Some derivatives of phthalazine, quinoxaline, and isoquinoline”, J. Chem. Soc., 777-782 (1948).
Nair, M.D., et al., “3-Chloroisocarbostyril & Its Chlorination Products”, Indian J. Chem., 467-470 (1967).
Jeffery, J.E. et al., “Synthesis of sibutramine, a novel cyclobutylalkylamine useful in the treatment of obesity, and its major human metabolites”, J. Chem. Soc., Perkin Trans. 1, 21, 2583-2589 (1996).
Gnecco, D. et al., “An Improved Preparation of 1-Methyl-4-Cyano-4-phenylpiperidine”, Org. Prep. Proced. Int., 18 (4), 478-480 (1996).
Fedorynski, M. et al., “Synthesis of 1-Arycyclopropanecarbonitriles under Phase-transfer Catalytic Conditions”, Org. Prep. Proced. Int., 27(3), 355-359 (1995).
Suzu

Affiliated with

Also associated with

Rating

Compositions useful as inhibitors of GSK-3 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions useful as inhibitors of GSK-3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions useful as inhibitors of GSK-3 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2713680